Preclinical studies have shown that celecoxib and trametinib association increase dabrafenib efficacy and reduce BRAF-inhibitor-induced keratoacanthoma and squamous cell carcinoma by PLX7420 [74,75]. Here, BRAF is linked to keratoacanthoma.